Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The second global trial of Axalimogene Filolisbac in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC)

Next Previous
Trial Profile

The second global trial of Axalimogene Filolisbac in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
  • 12 Jan 2017 New trial record
  • 09 Jan 2017 According to an Advaxis media release, the company intends to initiate this trial in the second half of 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top